Clinical trials
Age-Related Macular Degeneration clinical trials
Below are recruiting age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+ - NCT07555574Recruiting
New imaging technology to see retinal structures clearly
This research study tests a new camera technology that takes detailed pictures of the back of your eye (retina) to better understand eye diseases. Researchers want to compare images from people with eye conditions like diabetes-related eye disease, glaucoma, or age-related macular degeneration with healthy volunteers to see how the new imaging works.
Melbourne, VictoriaAges 18 years+ - NCT07547228RecruitingPhase 1/Phase 2
PRL3-zumab for advanced age-related macular degeneration
This study tests a new injectable medicine called PRL3-zumab for patients with advanced wet macular degeneration (nAMD) whose condition hasn't improved enough with standard treatments. The goal is to see if this new approach can help preserve or improve vision in people who have already tried at least two other eye injections.
SingaporeAges 18 years+ - NCT07531927Recruiting
Electrical Stimulation for Geographic Atrophy Vision Loss
This study tests whether gentle electrical stimulation applied to the eye can help slow vision loss from geographic atrophy, a common cause of blindness in older adults. The treatment uses a special device to stimulate the retina (the light-sensing tissue in the back of your eye).
HamburgAges 60 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT07502664Recruiting
A study on vision and navigation in inherited retinal disease
This study is looking at how people with inherited retinal disease that affects peripheral vision see and move around. It will test a new way to measure vision and navigation to see if it can help doctors understand how the disease affects daily life.
Irvine, CaliforniaAges 18 years+ - NCT06375239Recruiting
Study of tests for tracking vision in retinal disease
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
Irvine, CaliforniaAges 18 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT04985487Recruiting
Safety follow-up for brolucizumab in neovascular AMD
This study tracks the real-world safety of brolucizumab in adults with neovascular age-related macular degeneration (nAMD). If you’re already prescribed this medicine, the study may help confirm it continues to be safe and well-tolerated over time.
Daegu, Dalseo GuAges 18–100 - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT07456826Enrolling by invitationPhase 4
Comparing two eye numbing gels for shots
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Tyler, TexasAges 18 years+ - NCT07446582Recruiting
AI camera test for wet AMD detection
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
Woodbridge, New JerseyAges 40 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07443826RecruitingPhase 1/Phase 2
Gene therapy for age-related muscle loss and heart health
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
Coxen Hole, Bay IslandsAges 35–75 - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Manchester, ConnecticutAges 50 years+ - NCT07427160Recruiting
Study on best treatment for bleeding under the retina
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
Trento, TrentoAges 50 years+ - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT07338461Recruiting
High-resolution eye imaging study for healthy and eye disease volunteers
This study uses a special, high-resolution camera to take detailed pictures of the back of the eye. It is testing the camera's ability to see changes in the retina for people who are healthy or have age-related macular degeneration, diabetic retinopathy, or other conditions that affect autofluorescence patterns.
MilanAges 18 years+ - NCT07338513Enrolling by invitation
Home eye-tracking tool for wet AMD monitoring
This study tests a web-based eye-tracking tool to monitor vision impairment in people with wet age-related macular degeneration (AMD). You would use your computer at home, which could help reduce the need for frequent clinic visits.
SingaporeAges 55–99
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for age-related macular degeneration?
- Yes. Clin2 currently lists 134 recruiting age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.